Advanced search
Publication Cover
International Journal of General Medicine Volume 16, 2023 - Issue
Submit an article Journal homepage
127
Views
0
CrossRef citations to date
0
Altmetric
Infectious Diseases

14-Day Vonoprazan-Based Bismuth Quadruple Therapy for Treatment-Naïve Patients with Helicobacter pylori Infection: A Retrospective Comparative Study

Feifei Lu1 College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, 110167, People’s Republic of China;2 Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People’s Republic of China
,
Wentao Xu2 Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People’s Republic of China
,
Xiaoye Shi2 Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People’s Republic of China
,
Honglu Yu2 Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People’s Republic of China
&
Xingshun Qi1 College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning, 110167, People’s Republic of China;2 Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, Liaoning, 110840, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9448-6739
ORCID Icon
Pages 4279-4281 | Received 06 Jul 2023, Accepted 13 Sep 2023, Published online: 20 Sep 2023

References

  • Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420–429. doi:10.1053/j.gastro.2017.04.022
  • Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;2022:1.
  • Abdel-Aziz Y, Metz DC, Howden CW. Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther. 2021;53(7):794–809. doi:10.1111/apt.16295
  • Qian HS, Li WJ, Dang YN, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol. 2023;118(4):627–634. doi:10.14309/ajg.0000000000002086
  • Hu J, Mei H, Su NY, et al. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: a multicenter randomized controlled trial in China. Helicobacter. 2023;28:e12970. doi:10.1111/hel.12970
  • Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J. 2022;135(24):2899–2910. doi:10.1097/CM9.0000000000002546
  • Lu L, Wang Y, Ye J, et al. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: a single-center, open-label, noninferiority, randomized controlled trial. Helicobacter. 2023;28(1):e12940. doi:10.1111/hel.12940
  • Huang J, Lin Y. Vonoprazan on the eradication of Helicobacter pylori infection. Turk J Gastroenterol. 2023;34(3):221–226. doi:10.5152/tjg.2022.211041

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.